排序方式: 共有47条查询结果,搜索用时 31 毫秒
21.
Okuda K Hirose T Ishida H Kusumoto S Sugiyama T Ando K Shirai T Ohnishi T Horichi N Ohmori T Adachi M 《Cancer chemotherapy and pharmacology》2008,61(5):829-835
Purpose This trial was conducted to determine the maximum tolerated dose (MTD), principal toxicity, and recommended dose for phase
II study of the combination of nedaplatin and weekly paclitaxel in patients with advanced non-small cell lung cancer (NSCLC).
Methods Patients with previously untreated NSCLC, either stage IIIB with pleural effusion or stage IV, were eligible if they had a
performance status of 0–2, were 75 years or younger, and had adequate organ function. The respective doses of nedaplatin (day
1) and weekly paclitaxel (days 1, 8, and 15) studied were 80/60, 80/70, 80/80, 80/90, and 100/90 (mg m−2), repeated every 4 weeks.
Results From May 2004 through June 2005, 21 patients (18 men and 3 women; median age, 63 years; age range, 53–75 years) were enrolled.
The MTD was determined to be 100 mg m−2 of nedaplatin and 90 mg m−2 of weekly paclitaxel. Dose-limiting toxicities at the MTD were neutropenic fever and hepatic dysfunction. We recommend doses
of 80 mg m−2 of nedaplatin and 90 mg m−2 of weekly paclitaxel for phase II study. Grade 3–4 hematologic toxicities included neutropenia in 29% of patients, thrombocytopenia
in 0%, and anemia in 5%. Although the most frequent non-hematologic toxicity was hepatic dysfunction, all cases were only
mildly to moderately severe. Although two patients had grade 3 or 4 pulmonary toxicity due to Pneumocystis carinii pneumonia, these patients recovered after receiving trimetoprim-sulfamethoxazole, steroid therapy, and supplemental oxygen.
There were no treatment-related deaths. The overall response rate was 19.0% (95% confidence interval, 5.4–41.9%), and all
responses were in patients receiving the recommended doses. The median dose-intensities for nedaplatin and paclitaxel were
91.6 and 87.1%, respectively, of the planned doses.
Conclusion This combination chemotherapy is active and well tolerated and warrants phase II study. 相似文献
22.
Yoshida S Shiokawa S Kawano K Ito T Murakami H Suzuki H Sato Y 《Journal of medicinal chemistry》2005,48(22):7075-7079
During our search for therapeutic agents to treat diarrhea-predominant IBS, we found that 2-substituted benzoxazole derivatives have a characteristic 5-HT(3) receptor partial agonist activity with high affinity. Some of these compounds showed high in vitro metabolical stability, and 6g showed marked antidiarrhetic activity with little side effect of constipation in in vivo tests. Our results indicate that 5-HT(3) receptor partial agonists might be superior as therapeutic agents to the drugs currently used for IBS treatment. 相似文献
23.
Toida M Balázs M Treszl A Rákosy Z Kato K Yamazaki Y Matsui T Suwa T Hatakeyama D Makita H Mori S Yamashita T Shibata T Adány R 《Cancer Genetics and Cytogenetics》2005,159(2):99-104
In order to characterize the chromosomal alterations in ameloblastomas, a combination of comparative genomic hybridization (CGH) and fluorescence in situ hybridization (FISH) techniques was performed on 9 tumors. Chromosomal alterations including a gain at 1q and losses at 1pter, 10q, and 22q could be detected by CGH only in 1 tumor. Interphase FISH analysis, using centromeric probes for chromosomes 1, 10, and 22 as well as region-specific probes for 1p36 and 10q26, revealed the most frequent alterations to exist in the tumor with the abnormal CGH profile. These alterations included marked to slight increases of monosomic cells for chromosome 10 (91.5%), 10q26 (35.8%), 1p36 (24.4%), and chromosome 22 (18.8%), as well as significant elevations of trisomic cells for chromosome 1 (41.2%). Moreover, FISH analysis revealed a frequent loss of chromosome 22 in all tumors examined, except for one lesion, indicating that loss of the entire or a part of this chromosome is a common event in ameloblastomas, possibly being a predisposing factor to ameloblastoma tumorigenesis. 相似文献
24.
25.
Shima Y Saisaka Y Furukita Y Nishimura T Horimi T Nakamura T Tanaka K Shibuya Y Ozaki K Fukui Y Hamada M Nishioka Y Okabayashi T Taniki T Morita S Iwata J 《Journal of Hepato-Biliary-Pancreatic Surgery》2008,15(2):240-242
Xanthogranulomatous changes in the pancreas are extremely rare. A 66-year-old man presented with a 2-year history of epigastralgia.
Computed tomography scan revealed a 4-cm low-density area around the body of the pancreas. Magnetic resonance imaging demonstrated
that the mass appeared hyperintense on a T2-weighted image and isointense on a T1-weighted image. Based on a diagnosis of
invasive ductal carcinoma of the pancreas, distal pancreatectomy and splenectomy were performed. Sections examined from the
mass showed an aggregation of many foamy histiocytes, lymphocytes, and plasma cells. The surrounding pancreatic tissue showed
fibrosis and chronic inflammation. These findings suggested a xanthogranulomatous inflammation, and resulted in a diagnosis
of xanthogranulomatous pancreatitis. 相似文献
26.
A 50-year-old man who was the victim of an accident during work was taken to the hospital. His chest radiograph and computed
tomography (CT) scan showed pulmonary contusion, multiple rib fractures (left 5th to 11th ribs), hemopneumothorax, and splenic
rupture. On the fourth posttrauma day, CT showed bone particles of the ninth rib migrating to the thoracic aorta. These bone
particles were threatening to penetrate the thoracic aorta. He underwent operation to repair the flail chest by approximating
the left ribs and partial lung resection. After the operation the flail chest improved, enabling extubation the first day
after the operation. He was mobile and was discharged on the 17th postoperative day. A literature review revealed cases of
sudden death when such rib fragments lacerated the aorta. We therefore propose an early operation for patients who have multiple
bone fractures in the left chest. 相似文献
27.
Hirose T Shirai T Ishida H Ando K Sugiyama T Kusumoto S Hosaka T Nakashima M Ohmori T Adachi M 《Cancer chemotherapy and pharmacology》2007,60(2):267-274
We examined the safety and efficacy of the combination of docetaxel and irinotecan administered biweekly in patients with
refractory or relapsed advanced non-small cell lung cancer (NSCLC). Patients with previously treated NSCLC of stage III or
IV were eligible if they had a performance status of 2 or less, were 75 years or younger, and had adequate organ function.
From May 2003 through February 2006, 35 patients (27 men and 8 women; median age 64 years; age range 41–75 years) were enrolled.
Patients were treated every 4 weeks with docetaxel (33 mg/m2 on days 2 and 16) plus irinotecan (50 mg/m2 on days 1 and 15). None of the 35 patients achieved a complete response, but five achieved a partial response, for an overall
response rate of 14.3% (95% confidence interval, 4.8–30.3%). The median survival time was 8 months (range 2–29 months). The
median time to progression was 3 months (range 1–12 months). Grade 3 to 4 hematologic toxicities included leukopenia in 48.6%
of patients, neutropenia in 54.3%, and anemia in 25.7%. No patients had grade 3 to 4 diarrhea or nausea and vomiting. Although
one patient had grade 3 drug-induced interstitial pneumonia, all side effects were manageable, and there were no treatment-related
deaths. In conclusion, the combination of docetaxel and irinotecan administered biweekly is a safe and effective treatment
for refractory or relapsed NSCLC. However, the search for even more active regimens should be continued. 相似文献
28.
Yasuo Shima Yuichi Saisaka Yoshihito Furukita Takao Nishimura Tadashi Horimi Toshio Nakamura Kimiaki Tanaka Yuichi Shibuya Kazuhide Ozaki Yasuo Fukui Madoka Hamada Yutaka Nishioka Takahiro Okabayashi Toshikatsu Taniki Sojiro Morita Jun Iwata 《Journal of hepato-biliary-pancreatic sciences》2008,15(2):240-242
Xanthogranulomatous changes in the pancreas are extremely rare. A 66-year-old man presented with a 2-year history of epigastralgia. Computed tomography scan revealed a 4-cm low-density area around the body of the pancreas. Magnetic resonance imaging demonstrated that the mass appeared hyperintense on a T2-weighted image and isointense on a T1-weighted image. Based on a diagnosis of invasive ductal carcinoma of the pancreas, distal pancreatectomy and splenectomy were performed. Sections examined from the mass showed an aggregation of many foamy histiocytes, lymphocytes, and plasma cells. The surrounding pancreatic tissue showed fibrosis and chronic inflammation. These findings suggested a xanthogranulomatous inflammation, and resulted in a diagnosis of xanthogranulomatous pancreatitis. 相似文献
29.
Yasuaki Arai Atsushi Ohtsu Yozo Sato Takeshi Aramaki Ken Kato Madoka Hamada Kei Muro Yasuhide Yamada Yoshitaka Inaba Yasuhiro Shimada Narikazu Boku Yoshito Takeuchi Sojiro Morita Mitsuo Satake 《Journal of vascular and interventional radiology : JVIR》2012,23(10):1261-1267
PurposeTreatment of patients who have metastatic colorectal cancer (CRC) by using a combination of hepatic arterial infusion chemotherapy (HAIC) and systemic chemotherapy has resulted in promising clinical outcomes. Additionally, image-guided HAIC is reported to be less invasive and distribute drugs more accurately than surgical HAIC. The purpose of this study was to assess the combination of image-guided delivery of fluorouracil through HAIC and systemic irinotecan in a multicenter phase I/II study.Materials and MethodsTwenty-five patients with unresectable liver metastases from CRC were fitted with hepatic arterial catheter and port systems by using image-guided methods. Intraarterial fluorouracil (1,000 mg/m2) was administered on days 1, 8, and 15 of each treatment cycle. The dose of systemic irinotecan on days 1 and 15 was escalated from 75 mg/m2.ResultsNo dose-limiting toxicity was encountered during phase I, and the recommended dose of irinotecan was set at 150 mg/m2. Grade 3 or higher adverse events included hyperglycemia (15%), elevated γ-glutamyl transpeptidase levels (15%), and neutropenia (9%). The response rate and median survival time were 72% and 49.8 months (95% CI, 27.5–78.1 mo), respectively.ConclusionsThe combination of image-guided delivery of fluorouracil through HAIC and systemic irinotecan yielded favorable safety, response rate, and survival results. This combination should be evaluated in a large study. 相似文献
30.
Sojiro Morita M.D. Toshiya Takemura Shinichi Matsumoto Ryoichi Odani 《Cardiovascular and interventional radiology》1989,12(2):66-68
For management of the afferent loop syndrome, surgical revision such as jejunojejunostomy or Roux-en-Y conversion is the established
procedure. Percutaneous transhepatic catheter drainage was used as a method of palliative treatment of the obstructed afferent
loop in a patient with extensive mesenteric and peritoneal dissemination of gastric cancer. There were no procedural-related
complications, but severe bacterial cholangitis and septicemia occurred later. Our limited experience indicates that this
procedure may be risky, and that an additional drainage catheter of the bile duct may be needed when biliary stasis is present. 相似文献